Brief: Altamira Therapeutics Announces Launch Of Bentrio In Hong Kong By Its Partner Nuance Pharma
30/11/2022 14:39
Nov 30 (Reuters) - Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS ANNOUNCES LAUNCH OF BENTRIO IN HONG
KONG
BY ITS PARTNER NUANCE PHARMA
* ALTAMIRA THERAPEUTICS LTD - NUANCE PHARMA TO FILE FOR
MARKETING
APPROVAL IN MACAO, MAINLAND CHINA AND SOUTH KOREA IN 2023
* ALTAMIRA THERAPEUTICS LTD - UPON REACHING CERTAIN
MILESTONES,
NUANCE WILL ASSUME LOCAL PRODUCTION OF BENTRIO FOR ITS LICENSED
TERRITORY
* ALTAMIRA THERAPEUTICS - UPON REACHING CERTAIN MILESTONES,
NUANCE
WILL PAY TO CO A STAGGERED ROYALTY AT A HIGH-SINGLE TO
LOW-DOUBLE DIGIT PERCENTAGE
Source text for Eikon: ID:nGNX1tTL3w
Further company coverage: CYTO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering